Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany
| Autor: | Folgerdiena M. de Vries, Marcel A. Müller, N. Ahmad Aziz, Antonio Schmandke, Marie Luisa Schmidt, Thomas H. Schmidt, Monique M.B. Breteler, Christian Drosten, Anja Richter, Antje K.C. Echterhoff, Victor M. Corman |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Epidemiology virology [COVID-19] General Physics and Astronomy Antibodies Viral Immunoglobulin G Cohort Studies 0302 clinical medicine Applied immunology Seroepidemiologic Studies Germany immunology [SARS-CoV-2] 030212 general & internal medicine Aged 80 and over Immunoassay Multidisciplinary medicine.diagnostic_test biology methods [Immunoassay] Middle Aged Population Surveillance Female ddc:500 methods [Population Surveillance] Antibody Cohort study Adult immunology [Immunoglobulin G] Science prevention & control [COVID-19] Immunofluorescence General Biochemistry Genetics and Molecular Biology Article immunology [Antibodies Viral] 03 medical and health sciences Plaque reduction neutralization test Neutralization Tests methods [Neutralization Tests] medicine Seroprevalence Humans physiology [SARS-CoV-2] Aged business.industry SARS-CoV-2 COVID-19 General Chemistry diagnosis [COVID-19] Virology Antibodies Neutralizing immunology [Antibodies Neutralizing] 030104 developmental biology Viral infection biology.protein business |
| Zdroj: | Nature Communications Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021) Nature Communications 12(1), 2117 (2021). doi:10.1038/s41467-021-22351-5 |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-021-22351-5 |
| Popis: | To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24th and June 30th, 2020, seroprevalence was 0.97% (95% CI: 0.72−1.30) by immunoassay and 0.36% (95% CI: 0.21−0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly. Population-based studies of SARS-CoV-2 seroprevalence are needed to understand levels of immunity and antibody dynamics. Here, the authors show that the seroprevalence in Bonn, Germany was low ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|